{"name":"Philogen S.p.A.","slug":"philogen-s-p-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"Daromun","genericName":"Daromun","slug":"daromun","indication":"Other","status":"phase_3"},{"name":"L19TNF and CCNU in recurrent astrocytoma","genericName":"L19TNF and CCNU in recurrent astrocytoma","slug":"l19tnf-and-ccnu-in-recurrent-astrocytoma","indication":"Other","status":"phase_2"},{"name":"L19TNF and TMZ","genericName":"L19TNF and TMZ","slug":"l19tnf-and-tmz","indication":"Glioblastoma","status":"phase_2"},{"name":"[68Ga]Ga-OncoACP3","genericName":"[68Ga]Ga-OncoACP3","slug":"68ga-ga-oncoacp3","indication":"Other","status":"phase_1"},{"name":"[68Ga]Ga-OncoCAIX","genericName":"[68Ga]Ga-OncoCAIX","slug":"68ga-ga-oncocaix","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Intratumoral injections of L19IL2","genericName":"Intratumoral injections of L19IL2","slug":"intratumoral-injections-of-l19il2","indication":"Treatment of various cancers","status":"phase_2"},{"name":"L19IL2 + L19TNF","genericName":"L19IL2 + L19TNF","slug":"l19il2-l19tnf","indication":"Metastatic melanoma","status":"phase_3"}]}],"pipeline":[{"name":"Intratumoral injections of L19IL2","genericName":"Intratumoral injections of L19IL2","slug":"intratumoral-injections-of-l19il2","phase":"phase_2","mechanism":"L19IL2 is an immunocytokine that targets the EDB domain of fibronectin, which is overexpressed in tumor vasculature, and delivers IL-2 to the tumor microenvironment to stimulate an anti-tumor immune response.","indications":["Treatment of various cancers"],"catalyst":""},{"name":"Daromun","genericName":"Daromun","slug":"daromun","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"L19IL2 + L19TNF","genericName":"L19IL2 + L19TNF","slug":"l19il2-l19tnf","phase":"phase_3","mechanism":"L19IL2 + L19TNF is a bispecific antibody-cytokine fusion combination that targets tumor vasculature via the L19 antibody while delivering IL-2 and TNF directly to the tumor microenvironment.","indications":["Metastatic melanoma","Metastatic renal cell carcinoma"],"catalyst":""},{"name":"L19TNF and CCNU in recurrent astrocytoma","genericName":"L19TNF and CCNU in recurrent astrocytoma","slug":"l19tnf-and-ccnu-in-recurrent-astrocytoma","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"L19TNF and TMZ","genericName":"L19TNF and TMZ","slug":"l19tnf-and-tmz","phase":"phase_2","mechanism":"TNF-alpha inhibitor","indications":["Glioblastoma"],"catalyst":""},{"name":"[68Ga]Ga-OncoACP3","genericName":"[68Ga]Ga-OncoACP3","slug":"68ga-ga-oncoacp3","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"[68Ga]Ga-OncoCAIX","genericName":"[68Ga]Ga-OncoCAIX","slug":"68ga-ga-oncocaix","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNSzl0elNPblFtVjVtbWVsWURaRzhCQlBuUVBYRmI2WEZCcDhpVGNwM2pCQ1dISWoxWHUwUjl3OF9VYWM0SmttTW5IbHdGXzkwVUhuTWdSWG1PNW1PY3ZfUTRPTDdRYUM2WjI2NzFuM1dCUlBKQUtUTmJ5RUFwVjhaTmE3dlkzd3VFcUpYZHgxQXpXcmpFb1JuSklSQ3NvTzFNUF94OEMyM29qaWlha3NSMS1sbkhHVmF6RmFtSnNTMThpcmE0QzRfTWNzWC1GeUR2YTNv?oc=5","date":"2025-11-12","type":"trial","source":"scanx.trade","summary":"Sun Pharma: Mixed Results for Fibromun Cancer Drug Trial and Positive Data for Obesity Drug Utreglutide - scanx.trade","headline":"Sun Pharma: Mixed Results for Fibromun Cancer Drug Trial and Positive Data for Obesity Drug Utreglutide","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2025-06-25","type":"regulatory","source":"Medical Dialogues","summary":"Sun Pharma European partner Philogen pulls EMA application for skin cancer drug Nidlegy - Medical Dialogues","headline":"Sun Pharma European partner Philogen pulls EMA application for skin cancer drug Nidlegy","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-06-25","type":"deal","source":"Business Standard","summary":"Sun Pharma partner Philogen withdraws EU application for skin cancer drug - Business Standard","headline":"Sun Pharma partner Philogen withdraws EU application for skin cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQb2xGYy1jVXlJUzZUWDZaVl9pTXZIVThEUHRhaFJ2NjFxclppbEtrckhkaWhOcXJ3Z2Y3cWVEekhBdG5DZVZhOVVqaE9SM0x0MGJZYXBSMmtDaGpIWW9YOUUzbzhOS2dtbHFTQXFvQ3hUTzA3ckhMRHdQOGNTMGpOXzZfbzZyUEdEOENISlBQQW1oYWRod2QxQjlXaTZxWVczLVdySDhwNzFqX1poNHZldHJpZi1mSWhGTml3NGlB0gHDAUFVX3lxTE5Yd1lqRVNTMmdtanEzc0NBbHNuRlZWSWdmcHRNV0U3ZXNhc1ZaVnZWX3VTSXJPb3JiYnlST1lkVXRrYjFsS19lcGVQdDZqd1pTWHAyTGhnelVrOS16ZTFGMk81Y05ldm14VjFJSUR5VWhYa0NuNlVPZWM5WXlsbVZsRGdVdkNhdU9XREEtTU9mTmxHMGZFUEpRSVVhU3NrXzQ3bThpbzZwYU5QdzdtZmUzR25jQlYtdDNNVFE4bEQ3eENqYw?oc=5","date":"2025-02-10","type":"trial","source":"Express Pharma","summary":"Sun Pharma and Philogen complete patient enrollment for Phase III soft tissue sarcoma trial - Express Pharma","headline":"Sun Pharma and Philogen complete patient enrollment for Phase III soft tissue sarcoma trial","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-10-01","type":"pipeline","source":"ThePrint","summary":"Sun Pharma gets exclusive global rights to commercialise ‘Fibromun’, an anti-cancer immunotherapy product - ThePrint","headline":"Sun Pharma gets exclusive global rights to commercialise ‘Fibromun’, an anti-cancer immunotherapy product","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-10-01","type":"pipeline","source":"The Financial Express","summary":"Sun Pharma and Philogen enter into exclusive agreement for commercialising anti-cancer immunotherapy - The Financial Express","headline":"Sun Pharma and Philogen enter into exclusive agreement for commercialising anti-cancer immunotherapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPQUg3Y3JjanJULXgyV0ZjZW9RaHd6czJXU3FtRjBQZFJ3bmx1dEJOZzVaMUFUMUpSM25YYTR1cXEtbkdQM1RJSWJMMk51TlRKU0I1SDZUZko4TW12TTM5SDlVYUw2S0JQZUlIMXlFMVpkdEx3LVByLVBMc21GTWpxdUJLYnljZkFrSktNVkFkYVl0NXUyWm5Ic3Atb1FYYUXSAaQBQVVfeXFMUG9CZmdtVjZyX01xRWRGeHlZeTlTTVVfeVhpamNsMmgxVno5dlExMWdkWWxXOWhmNlN6QV8zS3ZtR1FhTWZpdFNaN1RuamtoY1hXUTBfYUxkMmQtR2NNR0FuTnl4dkJKUjhzQUdtR0xOLVlRZThMT2RjRkJXdlpZNmUwLW9tZDVlLUd0ZWlNTVNpcEVrUnVaMDBMcHFjNEcxaS1pbWU?oc=5","date":"2024-10-01","type":"pipeline","source":"Express Pharma","summary":"Sun Pharma and Philogen sign global licensing agreement for Fibromun - Express Pharma","headline":"Sun Pharma and Philogen sign global licensing agreement for Fibromun","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gJBVV95cUxNS29NQ0l1eW5Hc2xwOUp3bFBrdWRQUzZFQTBDMUlsbEZ6dkRCeXh6S1FNYU5JOUhZREZMSW9SbnI0YlNuUUhMUWx3bmIxN0Z4UEJXT1VNaDJVWmR1d1QySlBFZ2g0ZFVyMVlWOC1sMldtbU1RSDYyaGQyUmtDZ2FmU0tVZl9IanF5YkZqVHcySU81SjJuR3IwVmd5cXFELUE0Ri1CdFVFT1FOT05UWXFabTAwLVdLSUdyQUlkblJ1NV9IY3A1V1RfZm42blR0NmU1Zk4xRjZqd2RVTXlKcU9YTXNFRDJIcFFWd1hEbjNFUG5xN2hpQVZMVFFOZmJTbjJkSGtWSWVfRHpmbmZiUGF2bHkxdTFONVJoQmRoUFpibmRBdkEyMEVsaElZUTFCUDA2b1J0Ql9rODFkc0RhWUNkbUprbERGZlpiVTBLRzNaMlgwUQ?oc=5","date":"2023-05-30","type":"deal","source":"prnewswire.com","summary":"Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand - prnewswire.com","headline":"Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialt","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_2":3,"phase_3":2,"phase_1":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}